Skip to main content
. 2022 May 25;13:883655. doi: 10.3389/fphar.2022.883655

TABLE 1.

List of the studies involving PFS in this meta-analysis.

First author Year NCT Trial name Total number Phase Canner type Treatment 1 Patient number Treatment 2 Patient number Follow-up time PFS HR PFS CI lower limit PFS CI upper limit
Fehrenbacher L et al. (Fehrenbacher et al., 2018) 2018 NCT02008227 OAK 1225 3 Non small cell lung cancer Atezolizumab 613 Docetaxel 612 21 0.96 0.85 1.08
McDermott DF et al. (McDermott et al., 2018) 2018 NCT01984242 IMmotion150 204 2 Renal cell carcinoma Atezolizumab 103 Sunitinib 101 20.7 1.19 0.82 1.71
Powles T et al. (Powles et al., 2018) 2018 NCT02302807 IMvigor211 234 3 Urothelial carcinoma Atezolizumab 116 Chemotherapy 118 17.3 1.01 0.75 1.34
Eng C et al. (Eng et al., 2019) 2019 NCT02788279 IMblaze370 180 3 Colorectal cancer Atezolizumab 90 Regorafenib 90 7.3 1.39 1.00 1.94
Pujol JL et al. (Pujol et al., 2019) 2019 NCT03059667 IFCT-1603 73 2 Small Cell Lung Cancer Atezolizumab 49 Chemotherapy 24 13.7 2.26 1.3 3.93
Herbst RS et al. (Herbst et al., 2020) 2020 NCT02409342 IMpower110 554 3 Non small cell lung cancer Atezolizumab 277 Chemotherapy 277 13.4 0.77 0.63 0.94
Bang YJ et al. (Bang et al., 2018) 2018 NCT02625623 JAVELIN Gastric 300 371 3 Gastric/gastrooesophageal junction cancer Avelumab 185 Chemotherapy 186 10.6 1.73 1.4 2.2
Barlesi F et al. (Barlesi et al., 2018) 2018 NCT02395172 JAVELIN Lung 200 529 3 Non small cell lung cancer Avelumab 264 Docetaxel 265 T1:18.9 1.01 0.80 1.28
T2:17.8
Pujade-Lauraine E et al. (Pujade-Lauraine et al., 2021) 2021 NCT02580058 JAVELIN Ovarian 200 378 3 Ovarian cancer Avelumab 188 Pegylated liposomal doxorubicin 190 T1:18.2 1.68 1.32 2.60
T2:17.4
Huang J et al. (Huang et al., 2020) 2020 NCT03099382 ESCORT 448 3 Squamous cell carcinoma Camrelizumab 228 Chemotherapy 220 8.3 0.69 0.56 0.86
Sezer A et al. (Sezer et al., 2021) 2021 NCT03088540 EMPOWER-Lung 1 563 3 Non small cell lung cancer Cemiplimab 283 Chemotherapy 280 T1:10.8 0.54 0.43 0.68
T2:10.9
Siu LL et al. (Siu et al., 2019) 2019 NCT02319044 CONDOR 267 2 Squamous cell carcinoma Durvalumab+ 133 Durvalumab 67 T1:6.5 1.13 0.82 1.56
Tremelimumab T2:6.0
2 Squamous cell carcinoma Durvalumab+ 133 Tremelimumab 67 T1:6.5 0.73 0.53 1.01
Tremelimumab T2:5.2
Ferris RL et al. (Ferris et al., 2020) 2020 NCT02369874 EAGLE 736 3 Squamous cell carcinoma Durvalumab 240 Standard of care 249 T1:7.6 1.02 0.84 1.25
T2:7.8
3 Squamous cell carcinoma Durvalumab+ 247 Standard of care 249 T1:6.3 1.09 0.90 1.33
Tremelimumab T2:7.8
Planchard D et al. (Planchard et al., 2020) 2020 NCT02352948 ARCTIC 595 3 Non small cell lung cancer Durvalumab 62 Standard of care 64 9.1 0.71 0.49 1.04
3 Non small cell lung cancer Durvalumab+ 174 Standard of care 118 9.1 0.77 0.59 1.01
Tremelimumab
3 Non small cell lung cancer Durvalumab 117 Standard of care 118 9.1 0.87 0.65 1.16
3 Non small cell lung cancer Tremelimumab 60 Standard of care 118 9.1 1.25 0.88 1.77
Rizvi NA et al. (Rizvi et al., 2020) 2020 NCT02453282 MYSTIC 488 3 Non small cell lung cancer Durvalumab 163 Chemotherapy 162 10.6 0.87 0.59 1.29
3 Non small cell lung cancer Durvalumab+ 163 Chemotherapy 162 10.6 1.05 0.72 1.53
Tremelimumab
Bachelot T et al. (Bachelot et al., 2021) 2021 NCT02299999 SAFIR02-BREAST IMMUNO 199 2 Breast cancer Durvalumab 68 Chemotherapy 131 19.7 1.40 1.00 1.96
Bang YJ et al. (Bang et al., 2017) 2017 NCT01585987 NA 108 2 Gastric/gastrooesophageal junction cancer Ipilimumab 57 Best supportive care 51 24 1.44 1.09 1.91
Borghaei H et al. (Borghaei et al., 2015) 2015 NCT01673867 CheckMate 057 582 3 Non small cell lung cancer Nivolumab 292 Docetaxel 290 13.2 0.92 0.77 1.11
Brahmer J et al. (Brahmer et al., 2015) 2015 NCT01642004 CheckMate 017 272 3 Non small cell lung cancer Nivolumab 135 Docetaxel 137 11 0.62 0.47 0.81
Motzer RJ et al. (Motzer et al., 2015) 2015 NCT01668784 CheckMate 025 821 3 Renal cell carcinoma Nivolumab 410 Everolimus 411 14 0.88 0.75 1.03
Ferris RL et al. (Ferris et al., 2016) 2016 NCT02105636 CheckMate 141 361 3 Squamous cell carcinoma Nivolumab 240 Standard therapy 121 5.1 0.89 0.70 1.13
Hodi FS et al. (Hodi et al., 2016) 2016 NCT01927419 CheckMate 069 142 2 Melanoma Nivolumab+ 95 Ipilimumab 47 24.5 0·36 0.22 0.56
Ipilimumab
Carbone DP et al. (Carbone et al., 2017) 2017 NCT02041533 CheckMate 026 541 3 Non small cell lung cancer Nivolumab 271 Chemotherapy 270 13.5 1.19 0.97 1.46
Hodi FS et al. (Hodi et al., 2018) 2018 NCT01844505 CheckMate 067 945 3 Melanoma Nivolumab+ 314 Ipilimumab 315 T1：46.9 0.42 0.35 0.51
Ipilimumab T2:18.6
3 Melanoma Nivolumab 316 Ipilimumab 315 T1:18.6 0.53 0.44 0.64
T2:36
Larkin J et al. (Larkin et al., 2018) 2018 NCT01721746 CheckMate 037 405 3 Melanoma Nivolumab 272 Chemotherapy 133 24 1.00 0.78 1.44
Hellmann MD et al. (Hellmann et al., 2019) 2019 NCT02477826 CheckMate 227 299 3 Non small cell lung cancer Nivolumab+ 139 Chemotherapy 160 11.2 0.58 0.41 0.81
Ipilimumab
Kato K et al. (Kato et al., 2019) 2019 NCT02569242 ATTRACTION-3 419 3 Squamous cell carcinoma Nivolumab 210 Chemotherapy 209 17.6 1.08 0.87 1.34
Wu YL et al. (Wu et al., 2019) 2019 NCT02613507 CheckMate 078 504 3 Non small cell lung cancer Nivolumab 338 Docetaxel 166 8.8 0.77 0.62 0.95
Motzer RJ et al. (Motzer et al., 2020) 2020 NCT02231749 CheckMate 214 1096 3 Renal cell carcinoma Nivolumab+ 550 Sunitinib 546 42 0.88 0.75 1.04
Ipilimumab
Reardon DA et al. (Reardon et al., 2020) 2020 NCT02017717 CheckMate 143 369 3 Glioblastoma Nivolumab 184 Bevacizumab 185 9.5 1.97 1.57 2.48
Robert C et al. (Robert et al., 2020) 2020 NCT01721772 CheckMate 066 418 3 Melanoma Nivolumab 210 Dacarbazine 208 60 0.40 0.33 0.54
Zamarin D et al. (Zamarin et al., 2020) 2020 NCT02498600 NRG GY003 100 2 Ovarian Cancer Nivolumab+ 51 Nivolumab 49 NA 0.53 0.34 0.82
Ipilimumab
Baas P et al. (Baas et al., 2021) 2021 NCT02899299 CheckMate 743 605 3 Malignant pleural mesothelioma Nivolumab+ 303 Chemotherapy 302 29.7 1.00 0.82 1.21
Ipilimumab
Spigel DR et al. (Spigel et al., 2021) 2021 NCT02481830 CheckMate 331 569 3 Small cell lung cancer Nivolumab 284 Chemotherapy 285 15.8 1.41 1.18 1.69
Tannir NM et al. (Tannir et al., 2021) 2021 NA CheckMate 214 139 3 Renal cell carcinoma Nivolumab+ 74 Sunitinib 65 42 0.54 0.33 0.86
Ipilimumab
Herbst RS et al. (Herbst et al., 2016) 2016 NCT01905657 KEYNOTE-010 687 2/3 Non small cell lung cancer Pembrolizumab 344 Docetaxel 343 13.1 0.88 0.74 1.05
Hamid O et al. (Hamid et al., 2017) 2017 NCT01704287 KEYNOTE-002 359 2 Melanoma Pembrolizumab 180 Chemotherapy 179 28 0.58 0.46 0.73
Shitara K et al. (Shitara et al., 2018) 2018 NCT02370498 KEYNOTE-061 395 3 Gastric/gastrooesophageal junction cancer Pembrolizumab 196 Paclitaxel 199 8.5 1.27 1.03 1.57
Cohen EEW et al. (Cohen et al., 2019) 2019 NCT02252042 KEYNOTE-040 495 3 Ssquamous cell carcinoma Pembrolizumab 247 Standard of care 248 T1:7.5 0.96 0.79 1.16
T2:7.1
Fradet Y et al. (Fradet et al., 2019) 2019 NCT02256436 KEYNOTE-045 542 3 Urothelial cancer Pembrolizumab 270 Chemotherapy 272 27.7 0.96 0.79 1.16
Mok TSK et al. (Mok et al., 2019) 2019 NCT02220894 KEYNOTE-042 1274 3 Non small cell lung cancer Pembrolizumab 637 Chemotherapy 637 12.8 1.07 0.94 1.21
Reck M et al. (Reck et al., 2019) 2019 NCT02142738 KEYNOTE-024 305 3 Non small cell lung cancer Pembrolizumab 154 Chemotherapy 151 11.2 0.50 0.37 0.68
Robert C et al. (Robert et al., 2019) 2019 NCT01866319 KEYNOTE-006 834 3 Melanoma Pembrolizumab 556 Ipilimumab 278 57.7 0.57 0.48 0.67
André T et al. (André et al., 2020) 2020 NCT02563002 KEYNOTE-177 307 3 Colorectal cancer Pembrolizumab 153 Chemotherapy 154 32.4 0.60 0.45 0.80
Kojima T et al. (Kojima et al., 2020) 2020 NCT02564263 KEYNOTE-181 628 3 Esophageal Cancer Pembrolizumab 314 Chemotherapy 314 T1:7.1 1.11 0.94 1.31
T2:6.9
Popat S et al. (Popat et al., 2020) 2020 NCT02991482 ETOP 9-15 144 3 Malignant pleural mesothelioma Pembrolizumab 73 Chemotherapy 71 17.5 1.06 0.73 1.53
Shitara K et al. (Shitara et al., 2020) 2020 NCT02494583 KEYNOTE-062 506 3 Gastric/gastrooesophageal junction cancer Pembrolizumab 256 Chemotherapy 250 29.4 1.66 1.37 2.01
Kuruvilla J et al. (Kuruvilla et al., 2021) 2021 NCT02684292 KEYNOTE-204 304 3 Hodgkin lymphoma Pembrolizumab 151 Brentuximab vedotin 153 24 0.65 0.48 0.88

PFS = Progression-free survival. HR = Hazard ratio. CI = Confidence interval.